NCT04108208 2026-03-16
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
Clinical Trials
17 trialsNCT07474519 2026-03-16
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
Phase 4 Recruiting
NCT06862219 2026-03-06
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT03348969 2026-03-03
NICSA
Aarhus University Hospital
Phase 4 Completed
NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT03016741 2026-02-24
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Phase 4 Active not recruiting
NCT07278362 2026-02-23
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
University of Miami
Phase 4 Not yet recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT06627530 2026-02-11
COAction
Brazilian Clinical Research Institute
Phase 4 Active not recruiting
NCT06733350 2026-02-09
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
Roswell Park Cancer Institute
Phase 4 Suspended
NCT07252726 2026-02-09
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Ottawa Hospital Research Institute
Phase 4 Recruiting
NCT05348876 2026-01-30
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT04373564 2026-01-22
ODYSSEY
Guerbet
Phase 4 Recruiting
NCT06660862 2026-01-08
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
University of Chicago
Phase 4 Not yet recruiting
NCT05962541 2025-12-31
CUT-less
University of Roma La Sapienza
Phase 4 Recruiting
NCT02651948 2025-12-19
Transperineal, MRI-guided, Prostate Biopsy
University Hospital, Strasbourg, France
Phase 4 Completed
NCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed